Limited Value of Lymphangiography in Hodgkin's Disease

Brickner, Theodore J.; Boyer, Carl W.; Perry, Ronald H.

doi:10.1148/90.1.52

Cited by 10 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of therapy in our series (Figs. [2][3][4] are compatible with the current "state of the art" in the treatment of Hodgkin's disease by i r r a d i a t i~n '~~~~,~~~~~ (3 of the more recent Stage I11 patients were treated with adjunctive chemotherapy). Surprisingly, these results were achieved despite the fact that this group was treated over the period of a decade in which continual re-evaluation of staging methods as well as the extent of therapy were occurring.…”

Section: Discussionmentioning

confidence: 82%

Hodgkin's disease.Radiotherapeutic management at a cancer oriented community hospital

Saxe

Mandel

1978

Cancer

View full text Add to dashboard Cite

Seventy‐eight patients with Hodgkin's disease were treated with radiation therapy between July 1966 and July 1976 (30 Stage I, 28 Stage II, 20 Stage III). The mean follow‐up period is greater than 5 years. 90% of Stage I, 86% of Stage II, 65% of Stage III, and 82% (64/78) of all patients are NED after radiotherapy alone. Since laparotomy option (1970) 89% (50/56) of patients are NED. Fourteen patients were failures. Chemotherapy “rescued” 6 of 14. Seven have died, 1 is alive with disease, and 1 died of leukemia. Absolute survival is 90% (70/78). Failures were more frequent in patients with unfavorable histological types (9/14), and Stage III disease, primarily IIIS+ or B category (7/14). Sites of failures were mainly extranodal, primarily lung (10/14) and bone (2/14), and are consistent with hematogenous dissemination. Laparotomy performed in 41 patients identified unsuspected splenic involvement in 9 cases (22%), but was a distinct failure in confirming most “small node” positive lymphangiograms. Two patients developed acute myelocytic leukemia, both while NED 5 years posttherapy. One patient had also received adjunctive MOPP. There has been no impairment in the quality of survival that could be directly attributed to radiotherapy.

show abstract

Section: Discussionmentioning

confidence: 82%

Hodgkin's disease.Radiotherapeutic management at a cancer oriented community hospital

Saxe

Mandel

1978

Cancer

View full text Add to dashboard Cite

show abstract

“…Stages I and II of the disease may prove to be extensive (Stage III) after lymphography. The incidence of retroperitoneal node involvement has been stated to be from 0 to 36% in Stage I, and from 14 to 51% in Stage II (1). Some authors believe that Stage IB does not exist.…”

Section: Follow-upsmentioning

confidence: 99%

Current Status of Lymphography

Viamonte¹

1972

JAMA

View full text Add to dashboard Cite

Results of radiotherapeutic treatment of relapsing hodgkin's disease

Seydel¹,

Bloedorn²,

Wizenberg³

1969

Cancer

View full text Add to dashboard Cite

The survival of 39 patients with stage 1 or 2A Hodgkin's disease was determined actuarially. All received adequate radiotherapy. The 8‐year survival of 16 patients who remained free of disease was determined as 69%. The 13 patients who had relapses, classified as localized, and who received adequate radiotherapy for the relapse had an 8‐year survival of 24%. Ten patients with subsequent generalized relapse, who received palliative treatment, showed an 8‐year survival of 0%. Most relapses occurred in the second and third year after initial radiotherapy. It is concluded that prophylactic irradiation of apparently uninvolved lymph node bearing areas may improve the survival of patients with Hodgkin's disease.

show abstract

Limited Value of Lymphangiography in Hodgkin's Disease

Cited by 10 publications

References 5 publications

Hodgkin's disease.Radiotherapeutic management at a cancer oriented community hospital

Hodgkin's disease.Radiotherapeutic management at a cancer oriented community hospital

Current Status of Lymphography

Results of radiotherapeutic treatment of relapsing hodgkin's disease

Contact Info

Product

Resources

About